Indications for the use of Tranylcypromine and Trifluoperazine: (Parstelin)

Abstract

Thirty-two patients were treated with the combination of tranylcypromine and trifluoperazine (Parstelin). The patients fell into 3 clinical groups, namely, endogenous depression (7 patients), neurotic depressive reaction (10 patients) and phobic anxiety with some depressive features (15 patients). Satisfactory response was found in 10 out of the 15 patients with phobic symptoms. The response in the other 2 groups was not significant. Side effects were troublesome in the neurotic depressive reaction group. In the phobic group the symptoms of the patients who responded were inclined to recur when the treatment was discontinued. It is considered that it is a useful preparation in the treatment of some phobic patients, but one must expect that the patients are likely to have to remain on the drug for long periods of time.

60 Years of Combining Tranylcypromine

“…Two studies were controlled studies with data on TCP + lithium combination strategies, 26,27 and 10 were controlled studies with data on TCP + antipsychotic (all fist-generation antipsychotics [FGAs]) combination strategies 28–37 . Eight articles were noncontrolled studies including data on TCP + TCA combination strategies, 16,38–44 3 were noncontrolled studies including data on TCP + lithium or another mood stabilizer, 38,45,46 13 were noncontrolled studies including data on TCP + antipsychotic (FGAs and second-generation antipsychotics [SGAs]) combination strategies, 38,47–58 1 study included data on TCP + benzodiazepine combination, 38 1 included data on TCP + thyroxine, 59 and 1 on TCP + stimulant 60 . Twelve articles were case reports or case series comprising TCP + SSRI/SNRI/serotonin precursor combination strategies, 17,61–71 9 on TCP + TCA combination strategies, 72–80 9 on TCP + lithium combination strategies, 81–89 4 on TCP + other mood stabilizer other than lithium combination strategies, 72,90–92 5 on TCP + antipsychotics (FGAs and SGAs) combination strategies, 93–97 3 on TCP + benzodiazepine combination strategies, 98–100 3 on TCP + (es-)ketamine combination strategies, 101–103 1 on TCP + thyroxine combination, 18 1 on TCP + disulfiram combination, 104 6 on TCP + stimulant combination strategies, 72,105–109 1 on TCP + N -acetylcysteine, 110 1 on TCP + pindolol, 111 and 1 on TCP + l -DOPA 112 .…”

“…None was better rated than “2−”. From the noncontrolled studies, 2 were rated as “2−” 40,43 and 27 as “3,” 15,16,38,39,41,42,44–60 whereas 1 study yielded data for 5 compound subgroups 38 . All case reports and case series were rated as “3.” 17,18,61–109,111,112 …”

“…[19][20][21][22][23][24][25] Two studies were controlled studies with data on TCP + lithium combination strategies, 26,27 and 10 were controlled studies with data on TCP + antipsychotic (all fist-generation antipsychotics [FGAs]) combination strategies. [28][29][30][31][32][33][34][35][36][37] Eight articles were noncontrolled studies including data on TCP + TCA combination strategies, 16,[38][39][40][41][42][43][44] 3 were noncontrolled studies including data on TCP + lithium or another mood stabilizer, 38,45,46 13 were noncontrolled studies including data on TCP + antipsychotic (FGAs and second-generation antipsychotics [SGAs]) combination strategies, 38,[47][48][49][50][51][52][53][54][55][56][57][58] 1 study included data on TCP + benzodiazepine combination, 38 1 included data on TCP + thyroxine,…”

Detection and quantitation of a ring-hydroxylated metabolite of the antidepressant drug tranylcypromine

“…The increased brain levels of TCP following pretreatment with antipsychotics is of interest, since such drugs are sometimes given in conjunction with TCP in clinical situations (Lyons and Degerli, 1978). Pretreatments were administered at 3:00 p.m. Doses for all pretreatment drugs were 35 /amoles/kg.…”